Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Trial Profile

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms EXTEND
  • Sponsors Biogen
  • Most Recent Events

    • 26 Jun 2019 According to European Clinical Trials Database record, this study has been completed in UK(End Date: 2018-09-24).
    • 01 Mar 2019 Results from case series from multiple clinical trials (205MS203, 205MS301, 205MS302 and 205MS303) published in the Respiratory Medicine
    • 12 Dec 2018 This study has been discontinued in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top